Answers are grounded in this paper and cite their sources.
3128 Background: The TEM8 receptor (coded by ANTXR1) plays several roles in oncogenesis. Novel oncolytic therapies, such as the SVV-01 virus, uniquely bind this protein in tumor histologies such as small-cell lung cancer (SCLC). Emerging pre-clinical data suggest that TEM8-targeting therapies may convert immunologically “cold” tumor microenvironments (TME) into “hot” milieu with greater responses to immune checkpoint inhibitors (ICIs). Methods: NextGen sequencing of DNA (592 genes or whole exome)/RNA (whole transcriptome) was performed on SCLC ( N=1404) submitted to Caris Life Sciences (Phoenix, AZ). Mutations were defined as pathogenic SNVs/indels. ANTXR1 H and ANTXR1 L samples included those with >75 th and <25 th percentile expression, respectively. PD-L1 expression (22c3; Positive (+):TPS ³1%) was assessed by IHC. High tumor mutational burden (TMB-H) was defined as ≥10 mutations per MB. Cell infiltration in the TME was estimated by QuantiSEQ. Gene expression profiles were analyzed for transcriptional signatures predictive of response to immunotherapy (T cell-inflamed) and MAPK pathway activation score (MPAS). Real-world median overall survival (mOS) was assessed from insurance claims data, and Kaplan-Meier estimates were calculated for molecularly defined subpopulations of patients. Mann-Whitney U and X 2 /Fisher-Exact tests were applied where appropriate, with P-values adjusted for multiple comparisons ( p<0.05). Results: No pathogenic mutations were significantly associated with ANTXR1 H vs L tumors ( p>0.05 for all), along with no differences in the prevalence of TMB-H (28.6% vs 36.3%, p=1) or PDL1+ (45.0%: vs 35.0%, p=1). However, a greater proportion of B cells (6.53 % vs 5.12%, p<0.001), M1 (1.63% vs 0.37%, p<0.001) and M2 macrophages (3.40% vs 1.50%, p<0.001) were observed in ANTXR1 H TME, which were more frequently classified as T cell-inflamed compared to ANTXR1 L TME (23% vs 5%, p<0.001). ANTXR1 H tumors also had higher MPAS compared to ANTXR1 L (1.36 vs -1.86 arbitrary units, p<0.001). There was no significant difference in mOS between ANTXR1 H vs L tumors (12.2 vs 10.5 months, HR: 0.95, p=0.678). Conclusions: Increased B cell, M1 and M2 macrophage infiltrates, and increased prevalence of T-cell inflamed tumors in ANTXR1 H TME suggest that these patients with SCLC may respond preferentially to ICI. A Phase 1 trial incorporating SVV-01 along with ICI is underway. Prospective investigation of molecular associations and clinical outcomes related to ANTXR1 expression in SCLC is warranted.
No takes yet. Share an insight, caveat, or question.
Kareff et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: